Most of what gets reported is transient: nausea, facial flushing, a stretching and yawning reflex, reduced appetite, and spontaneous erections in men. Those came from two small trials in the late 1990s and 2000. The urgent list is short, separate, and drawn from emergency case reports: unresolving priapism, stimulant-like collapse with muscle breakdown, seizure with vision loss, and sudden flank pain.
Two evidence bases that do not overlap
The confusion here comes from mixing two kinds of record. The everyday effects were catalogued in controlled research settings decades ago, in trials that had nothing to do with tanning. The dangerous ones come from people arriving in emergency departments after buying an unregulated product online.
The trials were tiny. A double-blind placebo-controlled crossover study in the Journal of Urology in 1998 enrolled ten men with psychogenic erectile dysfunction. A second crossover study in Urology in 2000 enrolled ten men with organic risk factors. Together that is twenty subjects, studied under supervision with pharmaceutical-grade material, which resembles nothing about repeated self-injection of a gray-market powder over months.
What the small trials recorded
In the 1998 study, clinically apparent erections developed in eight of ten men, and nausea, stretching and yawning, and decreased appetite were reported more often after the active injection than after placebo, none requiring treatment. In the 2000 study, reported erections followed 12 of 19 active injections against one of 21 placebo doses, sexual desire scores were higher, and four of 19 injections involved severe nausea.
Two points follow. The erection effect is not incidental but a central pharmacological action of melanocortin agonism, which is why a related molecule was later developed specifically for sexual dysfunction. And severe nausea was not rare even in a supervised setting with a known quantity of drug.
The stretching and yawning reflex is characteristic of melanocortin agonists and is a reminder that this compound acts centrally, not just on skin. So is the appetite reduction.
What the emergency literature records
The serious events sit in a different literature and each is documented as an individual patient. Priapism appears in three separate reports, in Clinical Toxicology, BMJ Case Reports, and Sexual Medicine. A 2012 Clinical Toxicology report describes a man presenting two hours after injection with a heart rate peaking at 146, tremor, sweating, dilated pupils, and agitation, whose creatine kinase climbed to 17,773 IU/L, requiring three days of intensive care. Posterior reversible encephalopathy syndrome appears in Annals of Internal Medicine, renal infarction in CEN Case Reports.
The FDA’s summary of this compound, on its page listing bulk drug substances that may present significant safety risks, names four of these: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. That is a regulator restating the case record, not an incidence estimate.
Sorting the two lists
| Effect | How it presents | Evidence class | Response |
|---|---|---|---|
| Nausea | Within an hour, can be severe | Small trials, 20 subjects total | Expected |
| Flushing | Warmth and redness, short lived | Trial and case descriptions | Expected |
| Stretching and yawning | Involuntary, first hour | Small trials | Expected, typical of the class |
| Reduced appetite | Hours after dosing | Small trials | Expected |
| Spontaneous erection | Within hours, in men | Primary trial endpoint | Urgent past four hours |
| Priapism | Erection that will not resolve | Three case reports | Emergency |
| Sympathomimetic toxidrome | Tachycardia, tremor, agitation | Case report, named by FDA | Emergency |
| Rhabdomyolysis | Muscle pain, dark urine | Case report, laboratory confirmed | Emergency |
| Encephalopathy syndrome | Headache, vision change, seizure | Case report, named by FDA | Emergency |
| Nevus change and melanoma | Weeks to months, painless | Multiple case reports | Needs examination |
The skin sits in a third category
Pigment change belongs to neither list, and treating it as a minor cosmetic effect is the most common misreading of this compound. It is not an emergency, and not benign background noise either. It is a surveillance problem that develops silently.
Because melanotan II drives melanin production systemically, it acts on melanocytes inside existing moles as readily as on surrounding skin. Reported consequences include crops of new nevi, darkening of existing moles, changes visible on dermoscopy, new lentigines, pigmented nail bands, and mucosal pigmentation. A 2017 review in the International Journal of Dermatology found four published case reports of melanoma arising from existing moles during or shortly after use, while stating that conclusive evidence linking the two is absent.
This category deserves separate handling because the drug degrades the exact signals used to catch melanoma early. Change in color, size, and border is what triggers a biopsy. When a compound produces all three across dozens of benign lesions at once, both the person and the clinician lose their reference point.
The product itself blurs both lists
Predicting which category a given injection lands in runs into the supply problem. Chemists who bought vials from three online shops found all sold as 10 mg while containing between 4.32 mg and 8.84 mg, with unknown impurities of 4.1 to 5.9 percent in vials from two shops. Later forensic work characterized seized samples by high-resolution mass spectrometry precisely because identity could not be assumed.
The FDA’s stated concerns include immunogenicity risk for certain routes of administration due to potential aggregation or peptide-related impurities. For comparison, afamelanotide, the one melanocortin 1 receptor agonist with an approved US label, carries a postmarketing warning about serious hypersensitivity reactions including anaphylaxis, despite being manufactured to pharmaceutical standards and implanted by a trained clinician.
Why the access route shapes the risk
Melanotan II has no approved US product, no current DailyMed label, and no lawful compounding pathway. Its bulk drug substance nomination was withdrawn, and the FDA published the safety concerns it had identified. No licensed prescriber can supply it, which is a fact about the compound rather than a gap in any service. Elsewhere in compounded medicine the supervised model does exist, and telehealth operations such as Ways2Well, Invigor Medical, and formblends.com show what it consists of: an identifiable prescriber, a pharmacy that made the preparation, and a record. Melanotan II offers none of that, so sorting effects into common and urgent falls to the person injecting.
If a mole has changed since exposure, the next step is a dermatology appointment where the melanotan use is disclosed by name and date. That history changes how the examination is conducted.
The contrast with an approved category is stark. Because GLP-1 medicines like semaglutide carry an FDA label, patients can read what to expect before they ever inject. Providers such as Henry Meds, Ro, and HealthRX keep public pages on GLP-1 side effects, while NovoCare and LillyDirect connect people to branded manufacturer supply. Separating common effects from emergencies is far harder with melanotan II precisely because no provider stands behind it that way.
Frequently asked questions
Does severe nausea mean something is wrong?
Not necessarily. Severe nausea followed four of 19 injections in one supervised crossover study, so it appeared at a meaningful rate with pharmaceutical material. Nausea combined with racing heart, tremor, sweating, and agitation is a different picture, and that combination is what the published toxicology case describes.
At what point does an erection become an emergency?
Four hours is the standard threshold for priapism regardless of cause. Beyond that, oxygen depletion in trapped blood damages erectile tissue, and the chance of permanent dysfunction rises each hour. Three published case reports link melanotan use to priapism requiring urgent urological management.
Can the tanning effect be kept while avoiding the risks?
No, because they are the same mechanism. The receptor activity that darkens skin is the receptor activity that darkens moles, and the central actions that cause nausea and erections come from the same systemic exposure. There is no version of the effect that is confined to the skin a person wanted to tan.
What should someone do who used it months ago and feels fine?
Get a full skin examination and mention the exposure. Melanocytic change is painless and slow, so feeling fine carries very little information here. A baseline examination with dermoscopy gives a future clinician something concrete to compare against, which is the piece missing from most of these histories.
